| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
260,040,000 |
| Market
Cap: |
123.51(B) |
| Last
Volume: |
1,112,262 |
Avg
Vol: |
1,608,800 |
| 52
Week Range: |
$323.62 - $456.95 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 400 MIDCAP |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 543 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
34,832 |
156,170 |
271,197 |
631,666 |
| Total Sell Value |
$15,561,839 |
$65,781,555 |
$107,325,701 |
$215,119,054 |
| Total People Sold |
10 |
13 |
14 |
18 |
| Total Sell Transactions |
12 |
45 |
68 |
135 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lee Yuchun |
Director |
– • – |
2020-04-20 |
4 |
AS |
$269.97 |
$546,310 |
D/D |
(2,000) |
1,875 |
|
-1% |
|
| Lee Yuchun |
Director |
– • – |
2020-04-20 |
4 |
OE |
$57.27 |
$114,540 |
D/D |
2,000 |
3,875 |
|
- |
|
| Silva Paul M |
SVP & Controller |
• – – |
2020-04-13 |
4 |
AS |
$244.09 |
$213,650 |
D/D |
(859) |
14,932 |
|
10% |
|
| Silva Paul M |
SVP & Controller |
• – – |
2020-04-13 |
4 |
OE |
$90.29 |
$77,559 |
D/D |
859 |
15,791 |
|
- |
|
| Silva Paul M |
SVP & Controller |
• – – |
2020-04-06 |
4 |
AS |
$255.57 |
$1,249,993 |
D/D |
(4,891) |
14,932 |
|
5% |
|
| Silva Paul M |
SVP & Controller |
• – – |
2020-04-06 |
4 |
OE |
$155.57 |
$760,893 |
D/D |
4,891 |
19,823 |
|
- |
|
| Leiden Jeffrey M |
Executive Chairman |
• • – |
2020-03-31 |
4 |
D |
$234.01 |
$9,381,461 |
D/D |
(40,090) |
52,491 |
|
- |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2020-02-25 |
4 |
AS |
$229.72 |
$706,776 |
D/D |
(3,028) |
28,902 |
|
23% |
|
| Silva Paul M |
SVP & Controller |
• – – |
2020-02-25 |
4 |
AS |
$229.66 |
$252,127 |
D/D |
(1,080) |
14,932 |
|
23% |
|
| Parini Michael |
EVP, CL&AO |
• – – |
2020-02-25 |
4 |
AS |
$230.07 |
$707,005 |
D/D |
(3,028) |
26,838 |
|
23% |
|
| Arbuckle Stuart A |
EVP, Chief Commercial Officer |
• – – |
2020-02-25 |
4 |
AS |
$229.78 |
$849,418 |
D/D |
(3,634) |
35,179 |
|
23% |
|
| Tatsis Ourania |
SVP, CRO |
• – – |
2020-02-25 |
4 |
AS |
$229.57 |
$302,187 |
D/D |
(1,296) |
12,738 |
|
23% |
|
| Leiden Jeffrey M |
CEO & President |
• • – |
2020-02-25 |
4 |
AS |
$229.77 |
$2,463,046 |
D/D |
(10,550) |
92,581 |
|
23% |
|
| Kewalramani Reshma |
EVP and CMO |
• • – |
2020-02-25 |
4 |
AS |
$229.72 |
$848,371 |
D/D |
(3,634) |
26,626 |
|
23% |
|
| Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2020-02-25 |
4 |
AS |
$230.00 |
$788,402 |
D/D |
(3,376) |
32,915 |
|
23% |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2020-02-24 |
4 |
D |
$239.23 |
$577,980 |
D/D |
(2,416) |
31,930 |
|
- |
|
| Silva Paul M |
SVP & Controller |
• – – |
2020-02-24 |
4 |
D |
$239.23 |
$206,695 |
D/D |
(864) |
16,012 |
|
- |
|
| Parini Michael |
EVP, CL&AO |
• – – |
2020-02-24 |
4 |
D |
$239.23 |
$577,980 |
D/D |
(2,416) |
29,866 |
|
- |
|
| Arbuckle Stuart A |
EVP, Chief Commercial Officer |
• – – |
2020-02-24 |
4 |
D |
$239.23 |
$693,289 |
D/D |
(2,898) |
38,813 |
|
- |
|
| Tatsis Ourania |
SVP, CRO |
• – – |
2020-02-24 |
4 |
D |
$239.23 |
$247,842 |
D/D |
(1,036) |
14,034 |
|
- |
|
| Leiden Jeffrey M |
CEO & President |
• • – |
2020-02-24 |
4 |
D |
$239.23 |
$2,011,924 |
D/D |
(8,410) |
103,131 |
|
- |
|
| Wagner Charles F Jr |
EVP and CFO |
• – – |
2020-02-24 |
4 |
D |
$239.23 |
$129,663 |
D/D |
(542) |
17,274 |
|
- |
|
| Bozic Carmen |
EVP, GMDA |
• – – |
2020-02-24 |
4 |
D |
$239.23 |
$51,674 |
D/D |
(216) |
14,302 |
|
- |
|
| Kewalramani Reshma |
EVP and CMO |
• • – |
2020-02-24 |
4 |
D |
$239.23 |
$693,289 |
D/D |
(2,898) |
30,260 |
|
- |
|
| Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2020-02-24 |
4 |
D |
$239.23 |
$755,010 |
D/D |
(3,156) |
36,291 |
|
- |
|
3280 Records found
|
|
Page 25 of 132 |
|
|
4.77 (1.01%) 
